{
    "clinical_study": {
        "@rank": "39997", 
        "arm_group": [
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "hydrocortisone stress dosage", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "Exposure to stress alters the activity of the adrenomedullary, adrenocortical and\n      sympathetic nervous system, depending on the type and intensity of the stressor. Physical\n      exercise represents a stress condition influencing many systems in the body. Given a\n      workload of at least 70-85% of Vo2max, exercise is a potent stimulus of the\n      hypothalamic-pituitary-adrenal (HPA)-axis. The increased endogenous cortisol secretion\n      results in important metabolic and cardiovascular effects to maintain cellular and organ\n      homeostasis. Patients with Addison's disease are not able to meet the increased demand of\n      adrenal steroids in case of physical exercise, which may result in an impaired exercise\n      capacity and a prolonged post-exercise recovery. We hypothesize that a hydrocortisone stress\n      dose increases exercise capacity and improves post-exercise recovery in patients with\n      Addison's disease."
        }, 
        "brief_title": "Exercise Capacity and Recovery in Addison's Disease", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Addison's Disease", 
        "condition_browse": {
            "mesh_term": "Addison Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Addison's disease\n\n          -  18-50 years\n\n          -  stable glucocortiocid replacement therapy\n\n        Exclusion Criteria:\n\n          -  Presence of intercurrent (acute) infectious disease\n\n          -  Mental impairment (major depressive, anxiety, panic, adjustment, bipolar, psychotic,\n             posttraumatic or borderline personality disorder)\n\n          -  Presence of the following chronic diseases: diabetes mellitus, chronic obstructive\n             pulmonary disease, renal failure, chronic anaemia, malignancy, rheumatoid arthritis\n\n          -  Presence of the following cardiovascular conditions: unstable angina pectoris,\n             history of myocardial infarction, uncontrolled cardiac arrhythmias causing symptoms\n             or hemodynamic compromise, symptomatic (severe) aortic stenosis, uncontrolled\n             symptomatic heart failure, acute myocarditis or pericarditis, left main coronary\n             stenosis, moderate stenotic valvular heart disease, tachyarrhythmias or\n             bradyarrhythmias, hypertrophic cardiomyopathy and other forms of outflow tract\n             obstruction, high-degree atrioventricular block\n\n          -  History of pulmonary embolus or pulmonary infarction\n\n          -  Known aortic aneurysm\n\n          -  Severe hypertension (>170/100 mm Hg)\n\n          -  Medication that affects cardiovascular function (beta-blocker, calcium antagonist,\n             ACE-inhibitors, aldosterone-antagonists)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 1, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01657123", 
            "org_study_id": "33088"
        }, 
        "intervention": [
            {
                "arm_group_label": "placebo", 
                "description": "ergometry measurements", 
                "intervention_name": "ergometry", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "hydrocortisone stress dosage", 
                "description": "Ergometry measurements", 
                "intervention_name": "ergometry", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cortisol succinate", 
                "Hydrocortisone acetate", 
                "Hydrocortisone 17-butyrate 21-propionate", 
                "Hydrocortisone", 
                "Hydrocortisone-17-butyrate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "exercise capacity", 
            "Addison's disease"
        ], 
        "lastchanged_date": "August 2, 2012", 
        "location": {
            "contact": {
                "email": "l.c.c.j.smans@umcutrecht.nl", 
                "last_name": "Lisanne Smans, drs", 
                "phone": "0031616796646"
            }, 
            "contact_backup": {
                "email": "p.m.j.zelissen@umcutrecht.nl", 
                "last_name": "Pierre Zelissen, dr", 
                "phone": "0031887550686"
            }, 
            "facility": {
                "address": {
                    "city": "Utrecht", 
                    "country": "Netherlands", 
                    "zip": "3584 CX"
                }, 
                "name": "University Medical Center Utrecht"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Hydrocortisone Stress Dose on Exercise Capacity and Post-exercise Recovery in Patients With Addison's Disease", 
        "overall_contact": {
            "email": "l.c.c.j.smans@umcutrecht.nl", 
            "last_name": "Lisanne Smans, drs", 
            "phone": "0031616796646"
        }, 
        "overall_contact_backup": {
            "email": "p.m.j.zelissen@umcutrecht.nl", 
            "last_name": "Pierre Zelissen, dr", 
            "phone": "0031887550686"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "The Netherlands: Julius Clinical Research", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "power in Watt and duration in minutes", 
            "measure": "exercise capacity", 
            "safety_issue": "No", 
            "time_frame": "140 minutes"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01657123"
        }, 
        "responsible_party": {
            "investigator_affiliation": "UMC Utrecht", 
            "investigator_full_name": "Smans", 
            "investigator_title": "drs", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "UMC Utrecht", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "UMC Utrecht", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}